This site is intended for Healthcare professionals only.
×

Biocon,Mylan get EU approval for biosimilar of cancer drug


Biocon,Mylan get EU approval for biosimilar of cancer drug

“Ogivri, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, has been approved in the EU. The European Commission has granted marketing authorisation for Ogivri to our partner Mylan,” Biocon said in a regulatory filing.

New Delhi: Biotechnology major Biocon on Wednesday said the European Commission has approved and granted marketing authorisation to its biosimilar Ogivri, jointly-developed with Mylan, for the treatment of certain breast and stomach cancers.

“Ogivri, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, has been approved in the EU. The European Commission has granted marketing authorisation for Ogivri to our partner Mylan,” the company said in a regulatory filing.

Biocon said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had previously issued a positive opinion recommending approval of Ogivri as a biosimilar to Roche’s Herceptin (Trastuzumab) on October 18, 2018.

Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.

Also Read: USFDA completes Biocon Telangana plant inspection, no observations issued

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: PTI
0 comment(s) on Biocon,Mylan get EU approval for biosimilar of cancer drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted